PRMT5 inhibitor-resistant MCLs exhibited compensatory activation of multiple signaling pathways such as insulin receptors, PI3K, MAPK, and mTOR signaling in tumors, further using PRMT5 inhibitor (PRT-382) in combination with PI3K/mTORC1 and 2 (Omipalisib), or mTORC1 (Temsirolimus) or EIF1A (Silvestrol) could reverse this PRMT5 resistance in MCL [132]. The gene discussed is PRMT5; the disease is mantle cell lymphoma.